BioDelivery Sciences and Meda expand distribution deal
This article was originally published in Scrip
BioDelivery Sciences(BDSI) and Medahave expanded their commercial partnership. The Swiss company now has the global rights to distribute BioDelivery's lead product Onsolis (fentanyl buccal soluble film) in all countries except Taiwan and South Korea in return for $3 million. BDSI had previously licensed to Meda the rights to distribute Onsolis, a treatment for breakthrough pain in opioid-tolerant patients with cancer, in the US, Canada, Mexico and Europe. Meda will pay BDSI a $3 million advance on the anticipated $30 million milestone Meda owes for Onsolis. BDSI expects Onsolis to receive approval from the US FDA during the second quarter.